Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
about
New advances in targeted gastric cancer treatmentTaxanes in the Treatment of Advanced Gastric Cancer'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic ReviewA phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer.Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.Quality of life in the trastuzumab for gastric cancer trialSerum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma.Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation studyTargeted therapies for gastric cancer: current status.Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.RETRACTED: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patientsRecent advances in chemotherapy for advanced gastric cancerStandard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials.Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer.Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysisControversies and challenging therapeutic modalities in gastric cancer.Refining docetaxel-containing therapy for gastric cancer.Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer.Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomesIntegrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.The role of taxanes in the management of gastroesphageal cancerPalliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction follA phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma.Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinomaCapecitabine in advanced gastric cancer.Review of docetaxel in the treatment of gastric cancer.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Advanced gastric cancer: an update and future directionsPhase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxelMeasuring patient-reported outcomes in advanced gastric cancerUpper gastrointestinal tumors: current status and future perspectives.Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancerEsophageal cancer: current and emerging therapy modalities.Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
P2860
Q26738548-23E414D2-1D49-4B2F-B127-ADB40F79BB62Q26747708-2660970E-8981-463F-A929-04EB678ED7E6Q31125157-921F0648-6F36-4B7D-B677-CB611301784EQ33385867-0B1BF450-4FF3-413E-8521-4D4BA193C4B2Q33403949-9679C357-931B-405E-8326-8FAE947DF4ABQ33405235-F735CE0E-DB38-4207-9911-13ABF4568DE1Q33411751-3358B9D3-9A94-46FA-A6F8-08525D1D737FQ33829785-C8100C9D-3DF3-4982-BE5C-1A9B4173098EQ33879899-5C801F28-0B3F-49E5-AC24-EFE4AF5A4E08Q34204650-9D1C4F31-E9B1-4BE3-AA24-053075D7D83BQ34205672-5E8A4F0C-B15F-4381-B8D3-D04E8B08E375Q34241388-D7E18074-FEF5-4073-8031-F51C6A5651FEQ34252182-F4E82961-E2EC-4825-A1D3-45A9A5B28002Q34389753-8D5865E4-273A-40C9-8346-C49FAFF4A484Q34395983-A3C36CF9-48F2-4404-80CB-B0AF38E470F0Q34594956-D5F4F062-28E7-470C-8886-B42B1E337002Q34670947-31DAA1BB-F396-4DE4-8A3C-C83C21A90A83Q34672942-0B033502-B25A-4259-86C2-7FCBC2243507Q35129981-CD7E8C35-C1C6-4037-9E58-C6AB181E70D1Q35445166-74AA1102-4006-4A86-AE3D-79B020DEABFEQ35584360-D798AB03-1C00-45C7-A515-8AE1FD5F38AFQ35768031-26443164-CE94-4366-BA31-5B1B77403643Q35940367-63E2CF75-3553-44E3-8616-1B0DEA1B08AAQ36097240-11FA08C5-3F2D-4E37-BEF4-BE6A32867490Q36516605-EFF3CDA7-EBC8-40EA-B7A9-261A69386349Q36564026-5C3CC86E-D1B4-40A0-8936-0396C3F58437Q36691859-D0E6F960-6299-48C0-89E3-6FFE62657E78Q36822182-D289015F-2517-40F9-B5F2-439F7E3FB478Q36940910-88F09BAC-6937-4400-A0DD-C201DE2200FDQ36979346-D8624C40-E225-4EF3-B89F-40D52668C198Q37052880-4BC8E4F6-D6B4-4F95-8DD7-910170D3CBB4Q37077239-5B4CBE16-C09B-454E-A86E-974946694962Q37141665-F0247C57-B536-4A2A-ACD6-C7ED1B1055C3Q37142445-0708713D-98DD-40B6-9E47-856E4E09E5CCQ37153952-A0AC7FE4-DE64-4458-ABD0-BD177A808A08Q37181422-EAF6208F-808B-4693-80E5-DF91EAFF7027Q37183479-B4F8054F-A9BD-4012-9A54-CBA33DE402D7Q37235047-B637283B-74B0-4BDE-AB1B-3489713BD57BQ37256825-EFE1389F-90EB-4C64-801B-3FBD0C37370CQ37299565-9D920FD5-8D4D-43CD-BC91-B4C2BB0AD12E
P2860
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@en
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@nl
type
label
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@en
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@nl
prefLabel
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@en
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@nl
P2093
P921
P356
P1476
Quality of life with docetaxel ...... cinoma: the V-325 Study Group.
@en
P2093
Adriano Rodrigues
Alejandro Majlis
Corrado Boni
Edouard Voznyi
Eric Van Cutsem
Jaffer A Ajani
Lucile Awad
Manuel Constenla
Miguel Fodor
Sergei Tjulandin
P304
P356
10.1200/JCO.2006.08.3956
P407
P577
2007-08-01T00:00:00Z